ArticleBMC public health2025
Screening tests for hepatitis B, C and D in metropolitan France from 2016 to 2022: a map based on the National Health Data System with a focus on HDV hepatitis.
Article in BMC public health, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- From Diagnosis to Durability: A Review of the European Bulevirtide Experience and Practical Learnings for CHD Management.Liver international : official journal of the International Association for the Study of the Liver · 2026Review
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
backgroundAccording to the latest World Health Organization report, the incidence and mortality rates of viral hepatitis, including hepatitis delta virus (HDV) infection, have increased in recent years. The simultaneous screening of these viruses and HIV remains important for containing their spread or eliminating them. Many treatments are now available that can either cure or limit the complications of these infections. Delta infection, which affects 5% of hepatitis B (HBV)-positive patients, is largely underestimated, whereas the prevalence of HDV-related cirrhosis and hepatocellular carcinoma (HCC) is 3 to 5 times greater than that of HBV monoinfection. The real-life prevalence of HDV in metropolitan France has rarely been studied.
methodsThis study aimed to determine the number of HCV, HIV, HBV and HDV screening tests performed from 2016–2022 based on data from the French National Health Data System. We compared the results of HDV Ab tests with the number of expected HDV Ab tests, which was calculated based on the estimate of positive HBV screening in France (0.7%).
resultsFrom 2016–2022, 28,314,766 anti-HCV Ab tests, 29,463,042 anti-HIV Ab tests, 28,898,177 HBs Ag tests, 162,055 anti-HDV Ab tests and 21,963 HDV RNA tests were performed. We observed an increase of 39%, 30%, 45%, 130% and 206% respectively, during this period. Fifty-five percent of the expected anti-HDV Ab tests were carried out in 2016, 69% were carried out in 2020, and 94.7% were carried out in 2022. However, with respect to two specific populations in 2022, only 7.1% of pregnant women expected to be HBs Ag positive and 26% of patients monitored for chronic HBV infection underwent an anti-HDV Ab test. The patients screened for HBs Ag, anti-HCV Ab, anti-HIV Ab and anti-HDV Ab were mainly in the Ile de France and Provence-Alpes-Côte d’Azur regions. A total of 41.7% of the patients tested for anti-HDV Ab and 51.8% of the patients tested for HDV RNA had a precarious profile. HDV screening test prescribers were hospital-based, and HBV, HCV and HIV test prescribers worked mainly in the private sector.
conclusionHDV screening increased 2.3-fold from 2016 to 2022 but remained insufficient in some crucial populations.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.